[The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].
This clinical trial was designed to evaluate the efficacy and safety of indisetron hydrochloride an oral 5-HT3 receptor antagonist, for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer with paclitaxel/ carboplatin or docetaxel/carboplatin. Indisetron hydrochloride(8 mg)was administered orally to 46 gynecologic cancer patients at 0.5 hours before administration of the above chemotherapy agents. Number of patients who showed nausea or vomiting for 24 hours was counted. The complete vomiting inhibition rate at 24 hours after chemotherapy was 89.1%(41/46), and nausea inhibition rate was 71.7%(33/46). No serious adverse events were observed. These findings indicate that prophylactic administration of indisetron hydrochloride is safe and useful for inhibition of nausea/vomiting caused by cancer chemotherapy.
Ushijima
Kimio
K
Dept. of Obstetrics and Gynecology, Kurume University School of Medicine.
Wake
Norio
N
Kobayashi
Hiroaki
H
Hachisuga
Toru
T
Toki
Naoyuki
N
Masuzaki
Hideaki
H
Kotera
Kohei
K
Kawarabayashi
Tatsuhiko
T
Emoto
Makoto
M
Kamura
Toshiharu
T
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D011720:Pyrazoles; C500220:indisetron hydrochloride